The negative impact on Biogen's stock is primarily due to the company's soft guidance and declining sales of MS drugs, which outweigh the positive news of better-than-expected Alzheimer's treatment sales and a quarterly earnings beat. The below-consensus EPS outlook further dampens investor sentiment, leading to a likely short-term decline in stock price.